NIOX Group Reports Strong H1 Growth: Revenue Up 20%, Research Sales Double

Right, let’s dive into this NIOX Group update. On the face of it, H1 2025 paints a picture of a business executing well. The headline figures are undeniably positive, but as always, the devil – and the opportunity – lies in the detail.

H1 2025: The Numbers Tell a Strong Story

NIOX has kicked off 2025 with significant momentum:

• Revenue Surge: Group revenue hit approximately £25.2 million, a robust 20% increase (21% at constant currency) compared to H1 2024 (£21.0m).
• Clinical Core Holds Steady: The bread-and-butter clinical revenue grew 8% (9% cc) to £20.0m. This recurring revenue stream remains the bedrock.
• Research Revenue Explodes: The standout performer? Research revenue, which more than doubled, soaring 108% to £5.2m (from £2.5m). This surge is attributed to increased clinical trial activity for both asthma and COPD using FeNO testing.
• Profitability Boost: Adjusted EBITDA jumped an impressive 30% to approximately £9.2m (H1 2024: £7.1m), outpacing revenue growth and indicating operational leverage.
• Cash Resilience: Despite shelling out a chunky £5.0m dividend in June, the Group ended the half with £11.8m in cash, up from £10.9m at the end of 2024. That’s a strong signal of underlying cash generation.

Digging Deeper: Key Drivers and Considerations

Beyond the impressive top-line growth, a few critical points demand attention:

The Research Revenue Bonanza – Sustainable?

Make no mistake, that 108% jump in research sales is eye-catching and exceeded management’s own expectations. It highlights the growing adoption of FeNO testing as a valuable endpoint in respiratory drug trials. However, the caveat is crucial: NIOX explicitly states it’s “too early to determine whether this strong performance will continue throughout 2025.” Why? Because this revenue stream is inherently tied to the fluctuating R&D budgets and trial timelines of pharmaceutical companies. It’s a welcome boost, but investors shouldn’t bank on this doubling trend repeating every half-year just yet.

Margin Movement: A Slight Dip

Gross margin softened slightly to 70%, down about 2 percentage points from H1 2024. The explanation is logical: the booming research sales had a “higher mix of device-heavy” products. Devices typically carry lower margins than the recurring consumables used in clinical settings. It’s a natural consequence of the revenue mix shift towards research and isn’t necessarily alarming, but it’s a metric to watch as the product mix evolves.

Cost Control & Cash Generation

Overheads remained broadly stable year-on-year, excluding a small £0.3m one-off cost related to the withdrawn bid approach from Keensight. This cost discipline, combined with the revenue growth, fueled that healthy 30% EBITDA increase. The cash position, improving even after the significant dividend payment, is a testament to the business model’s cash-generative nature.

External Factors: FX and Tariffs

Currency fluctuations had minimal impact in H1, but NIOX flags a potential headwind if the US dollar weakens further against Sterling in H2. On tariffs, the message is reassuring: no impact seen so far, and the company believes it can pass on any potential cost increases via pricing if necessary.

Management’s Take: Focus Amidst Distraction

CEO Jonathan Emms struck a confident tone, crediting the team for delivering “strong growth in revenues and profits despite external distractions” (a clear nod to the Keensight saga). He emphasised the core clinical business’s strength, underpinned by recurring revenue, and pointed to future catalysts:

• US Market Acceleration: A key strategic focus remains deepening penetration of FeNO testing in the crucial US market.
• NIOX PRO® Launch: The upcoming launch of the new NIOX PRO® device represents a significant product refresh and potential growth driver.

Emms’s closing remarks – thanking shareholders and signalling confidence in continued progress – reinforce a positive outlook.

The Bottom Line: A Very Solid Start, But Eyes on H2

NIOX has delivered an H1 performance that ticks most boxes: strong double-digit revenue and profit growth, excellent cash management, and clear strategic execution. The dramatic rise in research revenue is a bonus, injecting significant extra cash, though its sustainability is the big question mark hanging over the second half.

The core clinical business continues to grow steadily, providing a reliable foundation. Slightly lower margins due to product mix are a watchpoint but explained. Management appears focused and confident, navigating past distractions and looking ahead to new product launches and market expansion.

This sets the stage for the interim results on 30th September. The key things investors will be looking for? Confirmation of the clinical business’s steady growth trajectory, any update on the sustainability of the research revenue surge, progress on the NIOX PRO® launch, and the impact (if any) of currency movements in H2. For now, NIOX is not just chugging along; it’s firing on several cylinders.